Select Publications
Conference Papers
2010, 'NON-SVR TO PEGINTERFERON ALFA-2A THERAPY AND RIBAVIRIN IS SRONGLY PREDICTED BY BASELINE FACTORS AND WEEK 8 ON-TREATMENT VIRAL LOAD IN HCV GENOTYPE (GT) 1 PATIENTS: NEW INSIGHTS FROM CART ANALYSIS OF THE CHARIOT STUDY', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 801A - 802A, presented at 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 29 October 2010 - 02 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000288775601314&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2010, 'Peginterferon Alfa-2a (40KD) Has a Wide Safety Margin in Patients Infected With Hepatitis C Virus Genotype 1: Pooled Data From Four Randomized Multicenter Studies', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, pp. S844 - S844, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000475844804188&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2010, 'DIFFERENCES IN EARLY VIROLOGICAL DECLINE IN INDIVIDUALS TREATED WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV SUGGEST A POTENTIAL BENEFIT FOR THE USE OF RIBAVIRIN', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Vienna, AUSTRIA, pp. S28 - S28, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Vienna, AUSTRIA, 14 April 2010 - 18 April 2010, http://www.journal-of-hepatology.eu/article/S0168-8278(10)60062-1/abstract
,2010, 'FACTORS ASSOCIATED WITH SPONTANEOUS CLEARANCE DURING ACUTE HEPATITIS C VIRUS INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, AUSTRIA, Vienna, pp. S411 - S411, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 14 April 2010 - 18 April 2010, http://dx.doi.org/10.1016/S0168-8278(10)61064-1
,2010, 'WEEK 4 HCV RNA IS THE OPTIMAL PREDICTOR OF SVR IN BOTH HIV POSITIVE AND NEGATIVE SUBJECTS WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, AUSTRIA, Vienna, pp. S116 - S116, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 14 April 2010 - 18 April 2010, http://dx.doi.org/10.1016/S0168-8278(10)60278-4
,2009, 'ADVANCED FIBROSIS IN GENOTYPE 1 HCV INFECTED PATIENTS RECEIVING ANTIVIRAL THERAPY IS ASSOCIATED WITH VIROLOGIC RELAPSE INDEPENDENT OF RAPID (RVR) AND EARLY (EVR) VIROLOGIC RESPONSE', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 1027A - 1028A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456001564&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2009, 'BASELINE AND ONTREATMENT PREDICTORS OF SVR TO PEGINTERFERON ALFA-2A THERAPY AND RIBAVIRIN IN HCV GENOTYPE (GT) 1 TREATMENT NAIVE PATIENTS: NEW INSIGHTS FROM THE CHARIOT STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 1033A - 1034A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456001574&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2009, 'EPIDEMIOLOGY OF RECENTLY ACQUIRED HEPATITIS C VIRUS (HCV) INFECTION IN HCV AND HCV/HIV INFECTED PARTICIPANTS IN THE ATAHC STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 668A - 668A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456000775&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2009, 'NO INCREASE IN INTRAHEPATIC MONONUCLEAR CELL OR STELLATE CELL ACTIVATION IN HIV-HBV CO-INFECTED INDIVIDUALS WITH ADVANCED HIV AND MILD LIVER DISEASE', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 993A - 994A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456001493&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2009, 'PEGINTERFERON ALFA-2A (40KD) (PEGIFN alpha 2A) HAS A WIDE SAFETY MARGIN IN COMBINATION WITH RIBAVIRIN (RBV) 1000/1200 MG/DAY IN PATIENTS INFECTED WITH HCV GENOTYPE 1: POOLED ANALYSIS OF DATA FROM FOUR RANDOMIZED MULTICENTER STUDIES', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 1030A - 1031A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456001569&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2009, 'PREVALENCE AND NATURE OF VIRAL MUTATIONS IN CHRONIC HEPATITIS B (CHB) PATIENTS ON ORAL ANTIVIRAL THERAPY (AVT): THE CHARM STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 488A - 489A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456000390&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2009, 'SIGNIFICANT HEMOGLOBIN (HB) DECLINE DURING PEGYLATED INTERFERON AND RIBAVIRIN THERAPY IN HCV GENOTYPE 1 IS ASSOCIATED WITH SUSTAINED VIROLOGIC RESPONSE (SVR): AN ANALYSIS FROM THE CHARIOT STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 1020A - 1021A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456001552&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2009, 'TREATMENT OF RECENT HEPATITIS C VIRUS INFECTION IN A PREDOMINANTLY INJECTION DRUG USER COHORT: THE ATAHC STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 723A - 723A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456000887&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2009, 'No increase in intrahepatic mononuclear or stellate cell activation in HIV-HBV co-infected individuals', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A292 - A292, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270551200196&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2009, 'Prevalence and characteristics of hepatitis B virus (HBV) mutations in chronic hepatitis B (CHB) patients on oral antiviral therapy (AVT): the charm study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A296 - A296, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270551200207&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2009, 'EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A 360 mu G/WEEK IN COMBINATION WITH RIBAVIRIN IN HEPATITIS C GENOTYPE I PATIENTS WITH CIRRHOSIS: ANALYSIS FROM THE CHARIOT STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, DENMARK, Copenhagen, pp. S221 - S221, presented at 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, DENMARK, Copenhagen, 22 April 2009 - 26 April 2009, http://dx.doi.org/10.1016/S0168-8278(09)60603-6
,2009, 'HIGH-DOSE PEGINTERFERON ALFA-2A (40KD) INDUCTION THERAPY AND STANDARD RIBAVIRIN ENHANCES EARLY BUT NOT SUSTAINED VIROLOGICAL RESPONSES IN HCV GENOTYPE 1 PATIENTS: FINAL CHARIOT STUDY RESULTS', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, DENMARK, Copenhagen, pp. S50 - S51, presented at 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, DENMARK, Copenhagen, 22 April 2009 - 26 April 2009, http://dx.doi.org/10.1016/S0168-8278(09)60126-4
,2009, 'IMPACT OF HEPATITIS C VIRUS INFECTION ON LIVER-RELATED MORTALITY IN A LARGE COMMUNITY-BASED COHORT OF INNER CITY RESIDENTS', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, DENMARK, Copenhagen, pp. S152 - S152, presented at 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, DENMARK, Copenhagen, 22 April 2009 - 26 April 2009, http://dx.doi.org/10.1016/S0168-8278(09)60404-9
,2009, 'IMPACT OF LOW-LEVEL HEPATITIS C VIRAEMIA AT WEEK 24 ON HCV TREATMENT RESPONSE IN GENOTYPE 1 PATIENTS', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, DENMARK, Copenhagen, pp. S220 - S220, presented at 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, DENMARK, Copenhagen, 22 April 2009 - 26 April 2009, http://dx.doi.org/10.1016/S0168-8278(09)60600-0
,2009, 'Hepatitis C virus reinfection following sustained virological response in injection drug users', in Suchtmedizin in Forschung und Praxis, pp. 231 - 234
,2008, 'PEGYLATED INTERFERON ALFA-2A (PEG-2A) PLUS RIBAVIRIN (RBV) FOR PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) ON OPIOID PHARMACOTHERAPY: VIROLOGICAL OUTCOMES, PSYCHOLOGICAL IMPACT AND SAFETY', in HEPATOLOGY, JOHN WILEY & SONS INC, CA, San Francisco, pp. 894A - 894A, presented at 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, CA, San Francisco, 31 October 2008 - 04 November 2008, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259757401690&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2008, 'TENOFOVIR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS ASSOCIATED WITH HIGH RATES OF HBV DNA SUPPRESSION AND HBEAG SEROCONVERSION IN THAI HIV-HBV COINFECTED PATIENTS', in HEPATOLOGY, JOHN WILEY & SONS INC, CA, San Francisco, pp. 712A - 713A, presented at 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, CA, San Francisco, 31 October 2008 - 04 November 2008, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259757401290&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2008, 'Prevalence and nature of viral mutations in chronic hepatitis B patients on antiviral therapy: the charm study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A264 - A264, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259960100179&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2008, 'Prevalence, Incidence and Risk Factors for Hepatitis C in HIV Negative and HIV Positive Homosexual Men', in Sexual Health, CSIRO Publishing, Australia, pp. 20 - 21, presented at Sexual Health, Perth, 17 September 2008 - 20 September 2008
,2008, 'Frequency of RVR and its utility as a predictor of treatment outcome in individuals treated within the Australian Trial in Acute Hepatitis c (ATAHC)', in Journal of Hepatology, Elsevier Science BV, Amsterdam, Netherlands, pp. S303 - S303, presented at Journal of Hepatology
,2008, 'IMPACT OF HEPATITIS C VIRUS INFECTION ON LIVER-RELATED MORTALITY IN A LARGE COMMUNITY-BASED COHORT OF INNER CITY RESIDENTS', in Journal of Hepatology, Elsevier Science BV, Amsterdam, Netherlands, pp. 401 - 402, presented at Journal of Hepatology
,2008, 'Baseline factors associated with rapid and early virological responses in HCV genotype 1 patients treated with induction dosing of pegylated interferon: The CHARIOT study', in Journal of Hepatology, Elsevier Science BV, Amsterdam, Netherlands, pp. S290 - S291, presented at Journal of Hepatology
,2008, 'Evidence of sexual transmission of hepatitis C virus infection among HIV-positive men who have sex with men in the Australian trial in acute hepatitis C (ATAHC) study', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A365 - A366
,2008, 'Factors associated with uptake of treatment for acute and early chronic hepatitis C virus infection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A344 - A344
,2008, 'Frequency of rapid virological response and its utility as a predictor of treatment outcome in individuals treated within the Australian trial in acute hepatitis C (ATAHC)', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A337 - A337
,2008, 'Immunity to acute hepatitis C and the influence of early therapy', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A356 - A356
,2008, 'Impact of illicit drug use on response to therapy during treatment for acute and early chronic HCV infection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A337 - A338
,2008, 'Incidence and risk factors for HCV reinfection and superinfection in individuals treated for acute/early chronic HCV infection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A343 - A344
,2008, 'INCIDENCE AND RISK FACTORS FOR HCV SUPERINFECTION AND REINFECTION IN INDIVIDUALS TREATED FOR ACUTE/EARLY CHRONIC HCV INFECTION', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 1844 - 1845, presented at Hepatology
,2008, 'Low rate of hepatitis C virus re-infection following sustained virological response among injection drug users having received treatment for HCV infection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A338 - A338
,2008, 'Modeling population-based chronic hepatitis B screening and treatment to prevent cirrhosis and liver cancer among high risk populations in Australia', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A358 - A359
,2008, 'Natural history of HCV reinfection and superinfection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A355 - A355
,2008, 'NATURAL HISTORY OF HCV SUPERINFECTION AND REINFECTION', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 1056 - 1057, presented at Hepatology
,2008, 'PEGYLATED INTERFERON ALFA-2A (PEG-2A) PLUS RIBAVIRIN (RBV) FOR PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) ON OPIOID PHARMACOTHERAPY: VIROLOGICAL OUTCOMES, PSYCHOLOGICAL IMPACT AND SAFETY', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 1310 - 1311, presented at Hepatology
,2008, 'Predictors and survival in hepatitis B-related hepatocellular carcinoma in New South Wales', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A343 - A343, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600028&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
,2008, 'Predictors of HCV treatment uptake and clinical trial participation among patients newly referred for HCV infection: the HCV clinical audit study', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A241 - A241, presented at Journal of Gastroenterology and Hepatology, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259960100133&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
,2008, 'Preparedness for candidate hepatitis C vaccine trials in people who inject drugs: challenges and opportunities', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A358 - A358
,2008, 'Tenofovir based HAART is associated with high rates of HBV DNA suppression and HBEAG seroconversion in thai HIV-HBV coinfected patients', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A336 - A336, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
,2008, 'TENOFOVIR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS ASSOCIATED WITH HIGH RATES OF HBV DNA SUPPRESSION AND HBEAG SEROCONVERSION IN THAI HIV-HBV COINFECTED PATIENTS', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 906 - 907, presented at Hepatology
,2008, 'The epidemiology of hepatitis C in Australia-a review of notifications, treatment uptake, and associated liver transplantations 1997-2006', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A379 - A379
,2008, 'Virological characteristics of a longitudinal HIV/HBV co-infected cohort prior to initiation of HBV-active HAART', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A336 - A337, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
,2007, 'Rapid and early virological response rates are increased with 12 week 360 mu g/wk peginterferon alfa-2A (40KD) and standard ribavirin in HCV genotype 1 treatment naive patients: Efficacy and safety analysis of the induction phase of the CHARIOT study', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 257A - 258A, presented at 58th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 02 November 2007 - 06 November 2007, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000249910400055&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2007, 'Viral load and ALT reductions associated with R1626 monotherapy, a novel nucleoside analog, in chronic hepatitis C genotype 1 patients', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, DC, Washington, pp. A779 - A779, presented at Digestive Disease Weeking Meeting/ASGE Postgraduate Course Meeting, DC, Washington, 19 May 2007 - 24 May 2007, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000245927606317&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2007, 'Design and characterization of R1626, a prodrug of the HCV replication inhibitor R1479 (4'-azidocytidine) with enhanced oral bioavailability', in ANTIVIRAL RESEARCH, ELSEVIER SCIENCE BV, CA, Palm Spring, pp. A35 - A35, presented at 20th International Conference on Antiviral Research, CA, Palm Spring, 29 April 2007 - 03 May 2007, http://dx.doi.org/10.1016/j.antiviral.2007.01.029
,2007, 'Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection', in Journal of Gastroenterology and Hepatology (Australia), pp. 615 - 633, http://dx.doi.org/10.1111/j.1440-1746.2007.04883.x
,